About 200 reports

Autoimmune phenomena in non-Hodgkin lymphoma.

  • Lung Cancer
  • World
  • AbbVie Inc.
  • Aduro BioTech, Inc.
  • Amgen Inc.
  • OPDIVO'S DEVELOPMENT IN NSCLC
  • PRESENTS AN OVERVIEW OF OPDIVO'S DEVELOPMENT PROGRAM IN NSCLC.

THIS STUDY INCLUDED BOTH PD-L## NEGATIVE TWO WEEKS) OR DOCETAXEL (##MG/ M (##%) AND PD-L## POSITIVE (##%) PATIENTS, BUT EXCLUDED PATIENTS WITH AUTOIMMUNE DISEASE, SYMPTOMATIC ILD, AND UNTREATED BRAIN METASTASIS.

  • Lung Cancer
  • Eli Lilly & Co.
  • Merck & Co., Inc.
  • Novartis AG
  • Pfizer Inc.

MONOCLONAL ANTIBODIES ARE ALSO HIGHLY UTILIZED IN AUTOIMMUNE DISEASE TREATMENT.

  • Lung Cancer
  • AstraZeneca PLC
  • Novartis AG
  • Pfizer Inc.
  • Roche Group

Orphanet Journal of Rare Diseases; ##: ##-## Leiter U and Garbe C (2008).

  • Lung Cancer
  • World
  • Market Size
  • Celgene Corporation
  • Merck & Co., Inc.

Infectious disease: Lymph node enlargement may be due to a variety of infectious or autoimmune diseases.

  • Lung Cancer
  • United States
  • Market Size
  • Illumina, Inc.
  • Trovagene, Inc.

Infectious disease: Lymph node enlargement may be due to a variety of infectious or autoimmune diseases.

  • Lung Cancer
  • United States
  • Market Size
  • Illumina, Inc.
  • Trovagene, Inc.

WITHOUT SUCH CHECKPOINTS, THE IMMUNE CELLS WILL ATTACK NORMAL CELLS OF THE BODY RESULTING IN AUTOIMMUNE DISEASES.

  • Lung Cancer
  • North America
  • United States
  • Incyte Corporation
  • Merck & Co., Inc.
  • Tyrosine Protein Kinase Receptor UFO (AXL Oncogene or AXL or EC 2.7.10.1) - Dormant Products
  • PRODUCTS UNDER DEVELOPMENT BY COMPANIES, H1 2018 (CONTD..4), H1 2018

Tyrosine Protein Kinase Receptor UFO (AXL Oncogene or AXL or EC 2.7.10.1) - Pipeline Review, H1 2018 Summary Tyrosine Protein Kinase Receptor UFO (AXL Oncogene or AXL or EC 2.7.10.1) - Tyrosine-protein kinase receptor UFO is an enzyme encoded by the AXL gene. It plays a role in various processes...

  • Lung Cancer
  • Oncology
  • Pharmaceutical
  • Therapy
  • Exelixis, Inc.
  • DORMANT PRODUCTS, H2 2017 (CONTD..1), H2 2017

One is a phase I trial vorinostat with intravenous temsirolimus for patients with metastatic disease.

  • Lung Cancer
  • Oncology
  • United States
  • Product Initiative
  • Acetylon Pharmaceuticals, Inc.

Medimmune undertake research in the areas of cancer treatment; respiratory; inflammation and autoimmune; and cardiovascular disorders and metabolic diseases.

  • Lung Cancer
  • Pharmaceutical
  • Therapy
  • United States
  • MedImmune, LLC
  • PLX-7486 - DRUG PROFILE
  • PLX-7486 - DRUG PROFILE

It focuses on therapy areas such as respiratory; cardiovascular and renal and metabolic diseases; and cancer, besides autoimmune, infection and neurological diseases.

  • Lung Cancer
  • United States
  • World
  • Product Initiative
  • Ignyta, Inc.

Monoclonal Antibody to Antagonize PD-## for Autoimmune Disorders and Oncology Bispecific mab is under development for the treatment of autoimmune diseases and cancer.

  • Cancer Immunotherapy
  • Lung Cancer
  • Oncology
  • Therapy
  • Merck & Co., Inc.

The granted patent claims cover AC-##' s composition of matter and uses to treat various inflammatory, autoimmune diseases such as Type I/ II diabetes, osteoarthritis and the complications of these diseases.

  • Chronic Disease
  • Lung Cancer
  • Therapy
  • United States
  • Product Initiative
  • ENTRECTINIB - DRUG PROFILE

It focuses on therapy areas such as respiratory; cardiovascular and metabolic disease (CVMD); and cancer, besides autoimmune, infection and neurological diseases.

  • Lung Cancer
  • United States
  • World
  • Product Initiative
  • Ignyta, Inc.
  • PLX-7486 - DRUG PROFILE
  • DS-6051 - DRUG PROFILE

It focuses on therapy areas such as respiratory; cardiovascular and metabolic disease (CVMD); and cancer, besides autoimmune, infection and neurological diseases.

  • Lung Cancer
  • United States
  • World
  • Product Initiative
  • Ignyta, Inc.
  • PIPELINE BY MERCK & CO INC, H1 2018
  • PIPELINE BY ADURO BIOTECH INC, H1 2018

The company develops drugs for cardiovascular, oncology, metabolic, pain, CNS, autoimmune and infectious disease applications.

  • Lung Cancer
  • Renal Cancer
  • United States
  • Product Initiative
  • Bristol-Myers Squibb Company
  • Pipeline by Etubics Corp, H2 2018
  • Pipeline by OSE Immunotherapeutics, H2 2018

OSE' s Effi-## is in preclinical development and targets autoimmune diseases and transplantation.

  • Lung Cancer
  • Therapy
  • World
  • Product Initiative
  • Etubics Corporation
  • Pipeline by OSE Immunotherapeutics, H1 2018
  • Pipeline by Etubics Corp, H1 2018

OSE' s Effi-## is in preclinical development and targets autoimmune diseases and transplantation.

  • Lung Cancer
  • Therapy
  • United States
  • Product Initiative
  • Etubics Corporation

Its other clinical programmes include TZLS-##, a human engineered anti-human CD## antibody intended for the treatment of autoimmune and inflammatory diseases.

  • Cancer
  • Lung Cancer
  • Pharmaceutical
  • Therapy
  • Cyclacel Pharmaceuticals, Inc.

Results Overall in BRCA positive patients (Parts ## and ##, n=##), disease control rate is ##. ##% and overall response rate (ORR) is ##% (Part ## ORR ##% and Part ## ##%).

  • Lung Cancer
  • Therapy
  • United States
  • Product Initiative
  • Cyclacel Pharmaceuticals, Inc.

Deal Type Deal in Brief TG Therapeutics Inc (TG Therapeutics) is a biopharmaceutical company which acquires, develops and commercializes pharmaceutical products for the treatment of B-cell malignancies and autoimmune diseases.

  • Lung Cancer
  • Pharmaceutical
  • Therapy
  • United States
  • Checkpoint

With the acquisition, Ignyta has evolved its business strategy from a sole focus on molecular diagnostics for autoimmune disease to an integrated " Rx/ Dx" focus on drug and biomarker discovery and development for cancer and immunology.

  • Lung Cancer
  • Pharmaceutical
  • United States
  • Company
  • Ignyta, Inc.
  • PEMBROLIZUMAB - DRUG PROFILE

Medimmune undertake research in the areas of cancer treatment; respiratory; inflammation and autoimmune; and cardiovascular disorders and metabolic diseases.

  • Blood Disease
  • Lung Cancer
  • Vaccine
  • United States
  • Merck & Co., Inc.
  • PEMBROLIZUMAB - DRUG PROFILE

Patients with active, non-infectious pneumonitis, an allogeneic transplant within the past five years (or more than five years but with graft-versus-host-disease [GVHD]), active autoimmune disease or a medical condition that required immunosuppression were ineligible for e

  • Lung Cancer
  • Therapy
  • United States
  • Product Initiative
  • Merck & Co., Inc.
  • entrectinib - Drug Profile

Among two evaluable MET- patients, one had stable disease and one had progression.

  • Lung Cancer
  • Therapy
  • United States
  • World
  • Product Initiative
  • PLX-7486 - DRUG PROFILE
  • ENTRECTINIB - DRUG PROFILE

It focuses on therapy areas such as respiratory; cardiovascular and metabolic disease (CVMD); and cancer, besides autoimmune, infection and neurological diseases.

  • Lung Cancer
  • Oncology
  • United States
  • Product Initiative
  • Exelixis, Inc.
  • target action, date of April 3, 2018.
  • PEXIDARTINIB HYDROCHLORIDE - DRUG PROFILE

Plexxikon announced in January that enrollment started for the first of two Phase ## clinical trials with PLX##, a novel, oral, targeted and highly selective Fms kinase inhibitor for the treatment of autoimmune diseases such as RA.

  • Lung Cancer
  • Lymphoma
  • Pharmaceutical
  • Therapy
  • Merck & Co., Inc.
  • target action, date of April 3, 2018.

Only ## patient had progressive disease.

  • Hospital
  • Lung Cancer
  • Therapy
  • United States
  • Product Initiative

Monoclonal Antibody for Autoimmune Disease - Drug Profile Monoclonal Antibody for Autoimmune Disease Ono Pharmaceutical Co., Ltd.

  • Lung Cancer
  • Pharmaceutical
  • Therapy
  • United States
  • Ono Pharmaceutical Co., Ltd.
  • entrectinib - Drug Profile

With the acquisition, Ignyta has evolved its business strategy from a sole focus on molecular diagnostics for autoimmune disease to an integrated " Rx/ Dx" focus on drug and bio marker discovery and development for cancer and immunology.

  • Lung Cancer
  • Therapy
  • United States
  • World
  • Product Initiative